Form 4: Amphastar Pharmaceuticals Executive Acquires Shares and Stock Options
SEC Form 4
Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, reports acquisition of shares and stock options.
Summary
- On March 4, 2024, Yakob Liawatidewi, EVP Corp Admin Center at Amphastar Pharmaceuticals, acquired 10,754 shares of common stock represented by restricted stock units (RSUs) that vest in four equal annual installments beginning March 4, 2025.
- Liawatidewi also acquired 22,655 employee stock options with an exercise price of $46.68, vesting in four equal annual installments beginning March 4, 2025, and expiring on March 4, 2034.
- Following the reported transactions, Liawatidewi directly owns 80,423 shares of common stock and indirectly owns 2,459 shares through the Yakob and Sunmoon Trust dated July 25, 2013, for which Liawatidewi serves as a trustee.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The acquisition of shares and options by an executive generally signals confidence in the company's future, but the Form 4 filing itself is simply a disclosure of transactions.
Positives
- The acquisition of shares and stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedules for the RSUs and stock options suggest a long-term commitment by the executive to the company's success.
Industry Context
Executive stock ownership is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded pharmaceutical companies.
- Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Pfizer also utilize similar equity-based compensation to incentivize their executives.
- The vesting schedules and exercise prices are generally aligned with industry norms to encourage long-term value creation.
Stakeholder Impact
- The reported transactions may have a slightly positive impact on shareholder sentiment, as they indicate confidence from a key executive.
Key Dates
| Date | Description |
|---|---|
| July 25, 2013 | Date of the Yakob and Sunmoon Trust. |
| March 4, 2024 | Date of the reported transactions (acquisition of shares and stock options). |
| March 4, 2025 | First vesting date for both the RSUs and stock options. |
| March 4, 2034 | Expiration date for the employee stock options. |
| March 6, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.